Shandong Weigao Orthopaedic Device Co. Ltd. A (688161) - Net Assets
Based on the latest financial reports, Shandong Weigao Orthopaedic Device Co. Ltd. A (688161) has net assets worth CN¥4.23 Billion CNY (≈ $618.83 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.19 Billion ≈ $759.56 Million USD) and total liabilities (CN¥961.73 Million ≈ $140.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688161 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.23 Billion |
| % of Total Assets | 81.47% |
| Annual Growth Rate | 14.16% |
| 5-Year Change | -8.34% |
| 10-Year Change | N/A |
| Growth Volatility | 33.35 |
Shandong Weigao Orthopaedic Device Co. Ltd. A - Net Assets Trend (2019–2025)
This chart illustrates how Shandong Weigao Orthopaedic Device Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See Shandong Weigao Orthopaedic Device Co. L (688161) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shandong Weigao Orthopaedic Device Co. Ltd. A (2019–2025)
The table below shows the annual net assets of Shandong Weigao Orthopaedic Device Co. Ltd. A from 2019 to 2025. For live valuation and market cap data, see 688161 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.16 Billion ≈ $608.65 Million |
+4.95% |
| 2024-12-31 | CN¥3.96 Billion ≈ $579.95 Million |
+2.30% |
| 2023-12-31 | CN¥3.87 Billion ≈ $566.90 Million |
-22.61% |
| 2022-12-31 | CN¥5.01 Billion ≈ $732.55 Million |
+10.32% |
| 2021-12-31 | CN¥4.54 Billion ≈ $664.00 Million |
+84.15% |
| 2020-12-31 | CN¥2.46 Billion ≈ $360.58 Million |
+31.16% |
| 2019-12-31 | CN¥1.88 Billion ≈ $274.93 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Weigao Orthopaedic Device Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 486.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.28 Billion | 54.94% |
| Other Components | CN¥1.87 Billion | 45.06% |
| Total Equity | CN¥4.14 Billion | 100.00% |
Shandong Weigao Orthopaedic Device Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shandong Weigao Orthopaedic Device Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sunward Intelligent Equipment Co Ltd
SHE:002097
|
$1.28 Billion |
|
Abacus Storage King
AU:ASK
|
$1.28 Billion |
|
Shenzhen Hello Tech Energy Co. Ltd. A
SHE:301327
|
$1.28 Billion |
|
Rimon Consulting & Management Services Ltd
TA:RMON
|
$1.28 Billion |
|
Zhejiang Goldensea Envi Tech C
SHG:603311
|
$1.28 Billion |
|
COSMO Pharmaceuticals SA
SW:COPN
|
$1.28 Billion |
|
WuXi Xinje Electric Co Ltd
SHG:603416
|
$1.28 Billion |
|
Ardent Health Partners, Inc.
NYSE:ARDT
|
$1.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Weigao Orthopaedic Device Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,953,519,924 to 4,144,501,202, a change of 190,981,278 (4.8%).
- Net income of 268,643,515 contributed positively to equity growth.
- Dividend payments of 127,686,420 reduced retained earnings.
- Other factors increased equity by 50,024,184.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥268.64 Million | +6.48% |
| Dividends Paid | CN¥127.69 Million | -3.08% |
| Other Changes | CN¥50.02 Million | +1.21% |
| Total Change | CN¥- | 4.83% |
Book Value vs Market Value Analysis
This analysis compares Shandong Weigao Orthopaedic Device Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.18x to 2.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥5.22 | CN¥21.84 | x |
| 2020-12-31 | CN¥6.84 | CN¥21.84 | x |
| 2021-12-31 | CN¥11.33 | CN¥21.84 | x |
| 2022-12-31 | CN¥12.51 | CN¥21.84 | x |
| 2023-12-31 | CN¥9.67 | CN¥21.84 | x |
| 2024-12-31 | CN¥9.88 | CN¥21.84 | x |
| 2025-12-31 | CN¥10.36 | CN¥21.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Weigao Orthopaedic Device Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.48%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.64%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.22x
- Recent ROE (6.48%) is below the historical average (12.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 23.60% | 28.06% | 0.49x | 1.72x | CN¥254.50 Million |
| 2020 | 22.76% | 30.62% | 0.57x | 1.30x | CN¥313.02 Million |
| 2021 | 15.23% | 32.05% | 0.40x | 1.19x | CN¥237.16 Million |
| 2022 | 12.00% | 29.19% | 0.34x | 1.20x | CN¥100.11 Million |
| 2023 | 2.90% | 8.75% | 0.25x | 1.32x | CN¥-274.58 Million |
| 2024 | 5.66% | 15.40% | 0.29x | 1.25x | CN¥-171.60 Million |
| 2025 | 6.48% | 17.64% | 0.30x | 1.22x | CN¥-145.81 Million |
Industry Comparison
This section compares Shandong Weigao Orthopaedic Device Co. Ltd. A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,442,122,104
- Average return on equity (ROE) among peers: 12.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Weigao Orthopaedic Device Co. Ltd. A (688161) | CN¥4.23 Billion | 23.60% | 0.23x | $1.28 Billion |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $4.98 Billion | -4.70% | 0.37x | $371.06 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $2.13 Billion | 17.09% | 0.37x | $3.63 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $6.77 Billion | 62.15% | 0.36x | $506.97 Million |
| Lepu Medical Tech Beijing (300003) | $10.54 Billion | 17.10% | 0.73x | $3.19 Billion |
| INKON Life Technology Co Ltd (300143) | $343.97 Million | 0.00% | 1.34x | $764.39 Million |
| Edan Instruments Inc (300206) | $1.25 Billion | 3.50% | 0.14x | $1.15 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.39 Billion | -4.69% | 0.82x | $735.30 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $761.02 Million | 12.92% | 0.49x | $467.29 Million |
| Sinocare Inc (300298) | $3.14 Billion | 14.20% | 0.47x | $1.17 Billion |
About Shandong Weigao Orthopaedic Device Co. Ltd. A
Shandong Weigao Orthopaedic Device Co., Ltd. engages in research, development, production, and sales of orthopedic medical devices. The company offers orthopedic implantable medical devices and orthopedic surgical instruments. It also provides spinal products, such as internal fixation systems for the cervical and thoracic/lumbar spine, and interbody fusion devices; trauma-related products includ… Read more